Health and Healthcare
Taiwan Liposome Advances Its Hydroxychloroquine Inhalation Study
Published:
Taiwan Liposome Co. Ltd. (NASDAQ: TLC) made progress in the fight against COVID-19 on Wednesday when it enrolled its first subject for its coronavirus treatment. This treatment differs from others because it is administered via an inhaler and includes the controversial hydroxychloroquine as part of the treatment.
The company previously received the go-ahead for this study from regulatory bodies in both Australia and Taiwan. The approval comes following the acceptance of Taiwan Liposome’s investigational new drug (IND) application with the Taiwan Food and Drug Administration last week.
In terms of the specifics, the first subject has been enrolled in the Phase 1 clinical trial of TLC19 for the treatment or prophylaxis of COVID-19. Ultimately, this study will evaluate the safety, tolerability and pharmacokinetics of single ascending doses of inhaled TLC19 in 30 healthy volunteers.
Management has said that it is very much looking forward to launching TLC19’s Phase 1 trial with the support of experienced, high-quality partners in Taiwan, as well as in Australia, which has an efficient and globally recognized regulatory environment with the bonus of government incentives and benefits and is a great place to conduct clinical trials for time-sensitive projects like TLC19.
Excluding Wednesday’s move, Taiwan Liposome stock had underperformed the broad markets with a retreat of about 14% year to date. In the past 52 weeks, the share price was down closer to 8%.
Taiwan Liposome stock traded up about 5% to $4.81 on Wednesday, in a 52-week range of $2.48 to $12.65. The consensus price target is $12.75.
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.